Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 53

recruiting
3 977
countries
28
conditions
2 105

3 664 trials match your criteria

Acromegaly

Recruiting

Study of Debio 4126, a new octreotide formulation, compared to placebo in patients with acromegaly who were previously treated with somatostatin analogs

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide

Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BGB-16673

Study of Blinatumomab Treatment in Patients with Systemic Lupus Erythematosus, Systemic Sclerosis, or Granulomatosis with Polyangiitis: Safety and Effectiveness Evaluation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab

Comparing mirikizumab versus azathioprine with glucocorticoids in newly diagnosed patients with moderate-to-severe ulcerative colitis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine

Constipation

Recruiting

Safety and tolerability study of sodium hydrogen carbonate and sodium dihydrogen phosphate suppository treatment in adult patients with chronic constipation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sodium dihydrogen phosphate

Safety Study of Tumor-Infiltrating Lymphocyte (TIL) Therapy for Patients with Metastatic Colorectal or Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin

Study of Darolutamide and Testosterone for Patients with Advanced Prostate Cancer Resistant to Standard Hormone Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone

Graves' disease

Recruiting

Study on the Effects and Safety of Rilzabrutinib for Adults with Graves' Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine

Study of mRNA-4157 and Pembrolizumab for Patients with Metastatic Melanoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157

Evaluation of SB-007 Safety and Efficacy in Patients with Stargardt Disease Type 1 (STGD1) Caused by ABCA4 Gene Mutations

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:ADENO-ASSOCIATED VIRUS VECTOR SEROTYPE 8 ENCODING THE ABCA4 PROTEIN, C-REGION

Cardiac failure

Recruiting

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.